Biocytogen H1 2026 Revenue Up 51.6%, Net Profit Surges 402.29%
Biocytogen reported first-half 2026 revenue of RMB 941 million, up 51.6% year on year, and net profit attributable to shareholders of RMB 241 million, up 402.29%. Basic earnings per share stood at RMB 0.54.
Biocytogen disclosed its interim report for the first half of 2026 on August 27. The company achieved operating revenue of RMB 941 million in the first half, up 51.6% year on year. Net profit attributable to shareholders of the listed company reached RMB 241 million, up 402.29% year on year. Basic earnings per share stood at RMB 0.54.